Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
CMMB Stock Forecast 2026-2027
$1.77
Current Price
$12.74M
Market Cap
Buy 2
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to CMMB Price Targets
+1,312.4%
To High Target of $25.00
+747.5%
To Median Target of $15.00
+182.5%
To Low Target of $5.00
CMMB Price Momentum
+9.9%
1 Week Change
+6.0%
1 Month Change
-64.9%
1 Year Change
+7.3%
Year-to-Date Change
-69.9%
From 52W High of $5.88
+31.1%
From 52W Low of $1.35
📊 TOP ANALYST CALLS
Did CMMB Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Chemomab is one of their latest high-conviction picks.
Latest CMMB Stock Price Targets & Analyst Predictions
Based on our analysis of 4 Wall Street analysts, CMMB has a bullish consensus with a median price target of $15.00 (ranging from $5.00 to $25.00). The overall analyst rating is Strong Buy (9.0/10). Currently trading at $1.77, the median forecast implies a 747.5% upside. This outlook is supported by 2 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Jeff Jones at Oppenheimer, projecting a 1,312.4% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CMMB Analyst Ratings
2
Buy
0
Hold
0
Sell
CMMB Price Target Range
Low
$5.00
Average
$15.00
High
$25.00
Current: $1.77
Latest CMMB Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CMMB.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Aug 27, 2025 | Oppenheimer | Jeff Jones | Outperform | Maintains | $25.00 |
| May 16, 2025 | Oppenheimer | Jeff Jones | Outperform | Maintains | $10.00 |
| Feb 20, 2025 | Maxim Group | Michael Okunewitch | Buy | Maintains | $7.00 |
| Nov 15, 2024 | Oppenheimer | Jeff Jones | Outperform | Reiterates | $11.00 |
| May 13, 2024 | Maxim Group | Michael Okunewitch | Buy | Initiates | $4.00 |
| May 6, 2024 | Oppenheimer | Jeff Jones | Outperform | Upgrade | $6.00 |
| Mar 8, 2024 | Oppenheimer | Jeff Jones | Perform | Maintains | $N/A |
| Dec 19, 2023 | Roth MKM | Dylan Dupuis | Buy | Reinstates | $7.00 |
| Oct 6, 2023 | Roth MKM | Dylan Dupuis | Buy | Initiates | $7.00 |
| Jun 7, 2023 | Oppenheimer | Jeff Jones | Perform | Downgrade | $N/A |
| Apr 18, 2023 | Oppenheimer | Jeff Jones | Outperform | Maintains | $7.00 |
| Mar 10, 2022 | Oppenheimer | Jeff Jones | Outperform | Maintains | $20.00 |
| Dec 7, 2021 | Aegis Capital | Buy | Initiates | $N/A | |
| May 26, 2021 | Cantor Fitzgerald | Overweight | Initiates | $N/A | |
| May 7, 2021 | Oppenheimer | Outperform | Initiates | $N/A |
Chemomab Therapeutics Ltd. (CMMB) Competitors
The following stocks are similar to Chemomab based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Chemomab Therapeutics Ltd. (CMMB) Financial Data
Chemomab Therapeutics Ltd. has a market capitalization of $12.74M with a P/E ratio of -1.2x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -69.5%.
Valuation Metrics
Market Cap
$12.74M
Enterprise Value
$990.80M
P/E Ratio
-1.2x
PEG Ratio
0.0x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+1.0%
Current Ratio
9.1x
Debt/Equity
0.0x
ROE
-69.5%
ROA
-38.9%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Chemomab Therapeutics Ltd. (CMMB) Business Model
About Chemomab Therapeutics Ltd.
What They Do
Develops therapeutics for fibrosis-related diseases.
Business Model
Chemomab Therapeutics operates as a clinical-stage biotechnology company that generates revenue through the development of innovative therapeutics. The company focuses on advancing its lead candidate, CM-101, which targets fibrosis and inflammation, and aims to enter Phase 3 trials following positive Phase 2 results. It seeks strategic collaborations and partnerships to enhance the commercialization of its therapies.
Additional Information
The company has received orphan drug and fast-track designations from regulatory agencies, highlighting its commitment to addressing significant unmet medical needs in fibro-inflammatory diseases. Its focus on rare conditions, such as primary sclerosing cholangitis, positions Chemomab favorably in the biotechnology sector.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
0
CEO
Dr. Adi Mor George Ph.D.
Country
Israel
IPO Year
2019
Website
www.chemomab.comChemomab Therapeutics Ltd. (CMMB) Latest News & Analysis
Latest News
Quick Summary
Chemomab is advancing partner discussions and preparing for the PSC Phase 3 trial launch for nebokitug in 2025.
Why It Matters
Chemomab's progress in partnering and advancing the PSC Phase 3 trial for nebokitug indicates potential growth and value creation, influencing investor sentiment and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Chemomab Therapeutics to Participate in Oppenheimer 36th Annual Healthcare Life Sciences Conference
2 months ago
Quick Summary
Chemomab Therapeutics (Nasdaq: CMMB) will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026, with CEO Dr. Adi Mor attending investor meetings.
Why It Matters
Chemomab's participation in a major healthcare conference highlights its visibility and potential for investment interest, which can impact stock performance and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Chemomab Therapeutics announced positive Phase 2 SPRING trial results for nebokitug in treating primary sclerosing cholangitis, supporting its advancement to a Phase 3 trial.
Why It Matters
Positive Phase 2 trial data for nebokitug in PSC could boost Chemomab's stock as it advances to Phase 3 trials, indicating potential for future revenue and market interest.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Chemomab Therapeutics CEO Adi Mor will speak at Oppenheimer's Movers in Rare Disease Summit on December 11, 2025, in New York City, highlighting the company’s work in fibro-inflammatory diseases.
Why It Matters
Chemomab's CEO's participation in a prominent summit highlights the company's focus on rare diseases, potentially boosting investor confidence in its development pipeline and future growth.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Chemomab Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update
5 months ago
Quick Summary
Chemomab Therapeutics reports near completion of Nebokitug Phase 3 design with FDA feedback. Positive Phase 2 data presented, cash runway through Q4 2026, and multiple partnership options advancing.
Why It Matters
Positive FDA feedback and EMA support for a single Phase 3 trial enhance Chemomab's prospects, potentially driving stock value as clinical data shows promising results in PSC treatment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Chemomab will present clinical data from the nebokitug Phase 2 trial in PSC at AASLD The Liver Meeting® 2025, highlighting three significant presentations.
Why It Matters
Chemomab's presentations at a major medical conference highlight promising clinical data, potentially boosting investor confidence and interest in the company's future prospects and market value.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About CMMB Stock
What is Chemomab Therapeutics Ltd.'s (CMMB) stock forecast for 2026?
Based on our analysis of 4 Wall Street analysts, Chemomab Therapeutics Ltd. (CMMB) has a median price target of $15.00. The highest price target is $25.00 and the lowest is $5.00.
Is CMMB stock a good investment in 2026?
According to current analyst ratings, CMMB has 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.77. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CMMB stock?
Wall Street analysts predict CMMB stock could reach $15.00 in the next 12 months. This represents a 747.5% increase from the current price of $1.77. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Chemomab Therapeutics Ltd.'s business model?
Chemomab Therapeutics operates as a clinical-stage biotechnology company that generates revenue through the development of innovative therapeutics. The company focuses on advancing its lead candidate, CM-101, which targets fibrosis and inflammation, and aims to enter Phase 3 trials following positive Phase 2 results. It seeks strategic collaborations and partnerships to enhance the commercialization of its therapies.
What is the highest forecasted price for CMMB Chemomab Therapeutics Ltd.?
The highest price target for CMMB is $25.00 from Jeff Jones at Oppenheimer, which represents a 1,312.4% increase from the current price of $1.77.
What is the lowest forecasted price for CMMB Chemomab Therapeutics Ltd.?
The lowest price target for CMMB is $5.00 from at , which represents a 182.5% increase from the current price of $1.77.
What is the overall CMMB consensus from analysts for Chemomab Therapeutics Ltd.?
The overall analyst consensus for CMMB is bullish. Out of 4 Wall Street analysts, 2 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $15.00.
How accurate are CMMB stock price projections?
Stock price projections, including those for Chemomab Therapeutics Ltd., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 9, 2026 5:08 AM UTC